Acute myeloid leukemia, t(8;21)(q22; q22.1)
MONDO:0850492An acute myeloid leukemia associated with t(8;21)(q22;q22) resulting in RUNX1-RUNX1T1 fusion protein expression. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules.
3095 clinical trials for this condition and its sub-types, 5 tagged with Acute myeloid leukemia, t(8;21)(q22; q22.1) itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC